Patents by Inventor Eok-Cheon KIM

Eok-Cheon KIM has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220023309
    Abstract: The present invention relates to a composition for preventing or treating cellular senescence-associated diseases comprising homoharringtonine as an active ingredient, and it was confirmed that the composition comprising homoharringtonine as an active ingredient exhibits a senolytics effect of selectively killing aging-induced fibroblasts and renal tubular cells, whereas aging-induced vascular endothelial cells and epithelial melanocytes and retinal pigmented epithelial cells, and exhibits a senomorphics effect of restoring the function and morphology of cells, and thus the homoharringtonine acts differently depending on the type of cells to effectively prevent or treat senile eye disease, tissue fibrosis disease, atherosclerosis, osteoarthritis, degenerative brain disease, chronic skin damage, obesity and diabetes caused by cellular aging and can be provided as a composition for whitening skin and life extension.
    Type: Application
    Filed: October 11, 2019
    Publication date: January 27, 2022
    Applicant: RESEARCH COOPERATION FOUNDATION OF YEUNGNAM UNIVERSITY
    Inventors: Jae-Ryong KIM, Eok-Cheon KIM, Kyong-Jin JUNG, Bum-Ho BIN, You Lim SON
  • Publication number: 20220023271
    Abstract: The present invention relates to a composition for preventing or treating cellular senescence-associated diseases comprising zotarolimus as an active ingredient, and in more detail, it was confirmed that zotarolimus exhibits a senomorphics effect of restoring the function and morphology of fibroblasts, umbilical vascular endothelial cells, renal tubular cells and retinal pigmented epithelial cells, in which senescence is induced and exhibits an effect of improving tissue fibrosis induced by cellular aging through the senomorphics effect and thus the composition comprising zotarolimus as an active ingredient can be provided as a composition for treating cellular senescence-associated diseases.
    Type: Application
    Filed: October 11, 2019
    Publication date: January 27, 2022
    Applicant: RESEARCH COOPERATION FOUNDATION OF YEUNGNAM UNIVERSITY
    Inventors: Jae-Ryong KIM, Eok-Cheon KIM, Kyong-Jin JUNG, You Lim SON
  • Publication number: 20220008377
    Abstract: The present invention relates to a composition for preventing or treating cellular senescence-associated diseases comprising salinomycin as an active ingredient, which acts differently depending on the type of senescent cells, and it was confirmed that salinomycin exhibits a senomorphics effect of restoring the function and morphology of fibroblasts and vascular endothelial cells in which senescence is induced and exhibits a senolytics effect of selectively killing aging-induced retinal pigmented epithelial cells, and exhibits a senomorphics effect of restoring the function and morphology of cells, and thus the salinomycin acts differently depending on the type of cells to effectively prevent or treat senile eye disease, tissue fibrosis disease, atherosclerosis, osteoarthritis, degenerative brain disease, chronic skin damage, obesity and diabetes caused by cellular aging and can be provided as a composition for life extension.
    Type: Application
    Filed: October 11, 2019
    Publication date: January 13, 2022
    Applicant: RESEARCH COOPERATION FOUNDATION OF YEUNGNAM UNIVERSITY
    Inventors: Jae-Ryong KIM, Eok-Cheon KIM, Kyong-Jin JUNG, You Lim SON